Conference Coverage
Latest News
ChatGPT in medicine: The good, the bad, and the unknown
Three-expert panel at DDW suggests clinicians should embrace the technology.
Latest News
Etrasimod looks safe for ulcerative colitis out to 2.5 years
If approved by the FDA, etrasimod could become the second agent in the S1P class approved for ulcerative colitis in the United States.
Conference Coverage
Esophageal diseases: Key new concepts
Novel care approaches for esophageal diseases. Highlights from the DDW AGA Postgraduate Course in esophageal conditions.
Conference Coverage
What is new in hepatology in 2023?
There has been a paradigm shift in risk stratification of cirrhosis and targets for prevention and treatment of decompensation.
Conference Coverage
Pediatric Crohn’s disease: Adalimumab plus methotrexate offers strong benefit
Children initiating treatment with adalimumab plus a low dose of methotrexate experienced a twofold reduction in treatment failure.
Conference Coverage
New treatments under study for celiac disease
Investigational treatment found to be highly effective in blocking gluten-specific T cells in celiac disease.
Conference Coverage
Multiple successive biologic to biosimilar switches deemed safe and effective
Triple switching from infliximab biologic to biosimilar for IBD found no new safety or efficacy concerns.
Conference Coverage
Unprecedented drop seen in early colorectal cancer cases due to aspirin use
The study confirms evidence from 30 years of research that suggests regular aspirin use reduces cancer risk.
Conference Coverage
Key Takeaways in Ulcerative Colitis From DDW 2023
Novel drug efficacy and safety data, thiopurine withdrawal, and the impact of high-dose opioid use are among the takeaways in...
Conference Coverage
Half of teens drop below obesity cutoff with semaglutide
The semaglutide findings are “historically unprecedented with treatments other than bariatric surgery.”